» Articles » PMID: 28223833

Autoimmune Atrophic Gastritis: Current Perspectives

Overview
Publisher Dove Medical Press
Specialty Gastroenterology
Date 2017 Feb 23
PMID 28223833
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

At present there is no universally accepted classification for gastritis. The first successful classification (The Sydney System) that is still commonly used by medical professionals was first introduced by Misiewicz et al in Sydney in 1990. In fact, it was the first detailed classification after the discovery of by Warren and Marshall in 1982. In 1994, the Updated Sydney System was proposed during the International Workshop on the Histopathology of Gastritis followed by the publication in by Dixon et al. Using the new classification, distinction between atrophic and nonatrophic gastritis was revised, and the visual scale grading was incorporated. According to the Updated Sydney System Classification, atrophic gastritis is categorized into multifocal (, environmental factors, specific diet) and corpus-predominant (autoimmune). Since metaplasia is a key histological characteristic in patients with atrophic gastritis, it has been recommended to use the word "metaplastic" in both variants of atrophic gastritis: autoimmune metaplastic atrophic gastritis (AMAG) and environmental metaplastic atrophic gastritis. Although there are many overlaps in the course of the disease and distinction between those two entities may be challenging, the aim of this review article was to describe the etiology, epidemiology, pathogenesis, diagnosis, clinical manifestations and treatment in patients with AMAG. However, it is important to mention that is the most common etiologic factor for the development of gastritis in the world.

Citing Articles

Monitoring the follow-up of autoimmune chronic atrophic gastritis using parietal cell antibodies and markers of gastric function.

Panozzo M, Antico A, Bizzaro N J Transl Autoimmun. 2025; 10:100273.

PMID: 39917315 PMC: 11800024. DOI: 10.1016/j.jtauto.2025.100273.


Cost-Effectiveness of Serum Pepsinogen as a Gastric Cancer Targeted Screening Strategy in the United States.

Oh A, Rustgi S, Hur C, In H Gastro Hep Adv. 2025; 4(2):100564.

PMID: 39866720 PMC: 11762188. DOI: 10.1016/j.gastha.2024.10.004.


Autoimmune gastritis diagnosed due to recurrent gastric neuroendocrine tumor: a case report.

Yang Q, Jin X, Lv X, Hu J Front Med (Lausanne). 2025; 11():1519819.

PMID: 39830375 PMC: 11739283. DOI: 10.3389/fmed.2024.1519819.


Effectiveness of serological markers of gastric mucosal atrophy in the gastric precancer screening and in cancer prevention.

Kotelevets S, Chekh S, Chukov S World J Gastrointest Endosc. 2024; 16(8):462-471.

PMID: 39155993 PMC: 11325870. DOI: 10.4253/wjge.v16.i8.462.


Coexistence of Guillain-Barré Syndrome and Subacute Combined Degeneration of the Spinal Cord Due to Autoimmune Gastritis: A Case Report and Literature Review.

Xiang H, Cai M Cureus. 2024; 16(6):e63084.

PMID: 39055481 PMC: 11270142. DOI: 10.7759/cureus.63084.


References
1.
Weis V, Petersen C, Mills J, Tuma P, Whitehead R, Goldenring J . Establishment of novel in vitro mouse chief cell and SPEM cultures identifies MAL2 as a marker of metaplasia in the stomach. Am J Physiol Gastrointest Liver Physiol. 2014; 307(8):G777-92. PMC: 4200317. DOI: 10.1152/ajpgi.00169.2014. View

2.
Wong H, Chu P . Immunohistochemical features of the gastrointestinal tract tumors. J Gastrointest Oncol. 2012; 3(3):262-84. PMC: 3418530. DOI: 10.3978/j.issn.2078-6891.2012.019. View

3.
Andres E, Serraj K . Optimal management of pernicious anemia. J Blood Med. 2012; 3:97-103. PMC: 3441227. DOI: 10.2147/JBM.S25620. View

4.
Saperstein D, Barohn R . Peripheral Neuropathy Due to Cobalamin Deficiency. Curr Treat Options Neurol. 2002; 4(3):197-201. DOI: 10.1007/s11940-002-0036-y. View

5.
Fossmark R, Sordal O, Jianu C, Qvigstad G, Nordrum I, Boyce M . Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012; 36(11-12):1067-75. DOI: 10.1111/apt.12090. View